LY 355703
Alternative Names: C-52; cryptophycin 52; Multi-drug resistance inhibitor cryptophycin 52Latest Information Update: 27 Mar 2009
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Depsipeptides; Lactams; Lactones
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 25 Mar 2003 A study has been added to the adverse events and Cancer therapeutic trials sections
- 12 Aug 2002 A phase II study in non-small cell lung cancer has been added to the Cancer therapeutic trials and adverse events sections
- 02 Nov 2001 Phase-II clinical trials in Non-small cell lung cancer in Germany (IV)